XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (69,903) $ (18,706)
Adjustments to reconcile net loss to net cash used in operating activities:    
Non-cash restructuring and impairment 0 2,943
Loss on impairment of goodwill 60,934 0
Depreciation and amortization expense 1,558 396
Stock-based compensation 1,222 365
Change in fair value of royalties payable (5,333) 0
Loss on disposals of property and equipment 0 44
Changes in operating assets and liabilities:    
Accounts receivable 25 21
Inventories (12) (14)
Prepaid expense and other current assets 913 (826)
Operating right-of-use asset and operating lease liabilities 5 0
Accounts payable (849) (528)
Accrued expenses (7,092) (3,028)
Interest payable (198) 0
Other liabilities 0 (210)
Net cash used in operating activities (18,730) (19,543)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (58) 0
Cash acquired as part of business combination 15 0
Net cash used in investing operations (43) 0
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock and warrants 238 13,614
Payments of offering costs related to the issuance of common stock and warrants 0 (1,168)
Proceeds from exercise of warrants 1,326 5,704
Proceeds from issuance of common stock in connection with the employee stock purchase plan 0 5
Payments of cost related to the warrant repricing (181) 0
Payments of convertible promissory notes and accrued interest (250) 0
Proceeds from the private placement of securities 8,000 0
Payments of offering costs related to the private placement of securities (640) 0
Net cash provided by financing activities 8,493 18,155
NET CHANGE IN CASH AND CASH EQUIVALENTS (10,280) (1,388)
CASH AND CASH EQUIVALENTS, beginning of period 15,859 15,045
CASH AND CASH EQUIVALENTS, end of period 5,579 13,657
SUPPLEMENTAL CASH FLOW INFORMATION    
Non-cash consideration for Catheter acquisition (Note 3) 72,544 0
Conversion of Series A Convertible Preferred Stock for common stock 1 0
Unpaid offering costs 0 1,356
Net proceeds receivable from sales of common stock 0 379
Proceeds receivable from sales of property and equipment 0 38
Cash payments for interest $ 198 $ 0